Latest Biotech News

EpiBiologics closed a $107 million Series B to advance its first‑in‑class protein‑degrading antibody programs, including lead candidate EPI‑326 targeting EGFR for non‑small cell lung and...

Cellares signed a collaboration with City of Hope to evaluate the Cell Shuttle manufacturing platform and Cell Q quality‑control automation for City of Hope’s glioblastoma CAR‑T program. The...

GlaxoSmithKline secured a non‑exclusive license to Noetik’s cancer foundation models with an upfront payment of $50 million, marking a new commercial structure for AI assets in drug discovery. The...

The US military’s health plan, Tricare, added coverage for Guardant Health’s Shield blood‑based colorectal cancer screening test, making the FDA‑approved assay available with no copay to...

Aktis Oncology priced an upsized initial public offering that raised about $318 million, marking the first biotech IPO of 2026. The Boston-based radiopharmaceutical developer will trade on Nasdaq...

Eli Lilly agreed to acquire Ventyx Biosciences for approximately $1.2 billion in cash to add oral NLRP3 inhibitors to its pipeline. Lilly said the acquisition strengthens its inflammation and...

OpenAI launched ChatGPT Health and pushed offerings for hospitals and health systems, bringing its conversational LLM directly into clinical and administrative workflows. The company positioned...

Aurora Therapeutics, cofounded by leaders from the Baby KJ personalized-CRISPR effort and backed by Menlo Ventures, launched with seed funding to pursue grouped or 'umbrella' regulatory pathways...

Boltz, a Massachusetts PBC spun out of MIT CSAIL research, launched Boltz Lab and open-source biomolecular AI models to accelerate structural prediction and therapeutic design. The company opened...

Parabilis Medicines closed a $305 million Series F financing to advance its corkscrew-shaped peptide platform and lead candidate zolucatetide into late-stage testing. The round, one of the largest...

Orca Bio raised $250 million in fresh financing to support the commercial launch of its T-cell therapy for complications from allogeneic stem cell transplants. The funds will be used to scale...

Cellares and City of Hope struck a collaboration to evaluate automated manufacturing and QC for City of Hope’s investigational CAR T program targeting glioblastoma. The agreement will test...

Aragen Biologics introduced CHOMax, an integrated CHO cell‑line development and early GMP manufacturing platform designed to move antibody programs from DNA to IND‑enabling clinical supply in...

Liquid‑biopsy firm Syantra launched a multicenter, 2,000‑subject study to support clinical implementation and market access for Onco‑ID Breast, its whole‑blood mRNA assay for early breast cancer...

Eli Lilly agreed to acquire Ventyx Biosciences in a roughly $1.2 billion all‑cash transaction, securing clinical‑stage NLRP3 inhibitor programs and near-term assets aimed at chronic inflammation....

Amgen agreed to acquire Dark Blue Therapeutics for up to $840 million plus royalties, adding the preclinical DBT‑3757 degrader directed at MLLT1 and MLLT3 and Dark Blue’s cancer discovery...

Radiopharmaceutical developer Aktis Oncology completed a Nasdaq IPO that raised about $318 million, marking the first biotech public offering of 2026. The company plans to use proceeds to advance...

Parabilis Medicines closed a $305 million Series F round to advance its Helicon‑peptide platform and push lead candidate zolucatetide toward later‑stage development. The financing, led by major...

AirNexis Therapeutics raised $200 million to acquire global rights to Haisco Pharmaceutical Group’s inhaled PDE3/4 inhibitor (HSK39004, coded AN01) and advance it in COPD outside China. Under the...

Cellares and City of Hope launched a collaboration to evaluate automated manufacturing and QC platforms for City of Hope’s investigational CAR T program targeting glioblastoma multiforme. City of...